Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-DOTA-ATH001
- Development stage
- Unknown
- Lead developer
- Antaros Medical
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]Ga-DOTA-ATH001 (also known as [68Ga]Ga-DOTA-Cys-ATH001) is a novel gallium-68-labeled Affibody-based radiopharmaceutical designed for positron emission tomography (PET) imaging of active fibrogenesis. It specifically targets platelet-derived growth factor receptor beta (PDGFRβ), a cell-surface receptor upregulated on activated mesenchymal cells, such as hepatic stellate cells, pericytes, and fibroblasts, which drive extracellular matrix deposition in fibrotic diseases. Developed by Antaros Tracer (a sister company of Antaros Medical) in collaboration with Uppsala University and Takeda, the tracer is being clinically evaluated as a non-invasive biomarker to detect, stage, and monitor active tissue scarring and treatment response in conditions such as metabolic dysfunction-associated steatohepatitis (MASH), primary sclerosing cholangitis (PSC), fibrostenotic Crohn's disease, ST-elevation myocardial infarction (STEMI), and heart failure with preserved ejection fraction (HFpEF).
- Other names
- [68Ga]Ga-ATH001[68Ga]Ga-DOTA-Cys-ATH00168Ga-ATH00168Ga-DOTA-ATH00168Ga-DOTA-Cys-ATH001DOTA-ATH001DOTA-ATH-001DOTA-ATH 001DOTA-Cys-ATH001DOTA-Cys-ATH-001DOTA-Cys-ATH 001
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on [68Ga]Ga-DOTA-ATH001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]Ga-DOTA-ATH001.